HER2 GENE MUTATION
Clinical trials for HER2 GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new HER2 GENE MUTATION trials appear
Sign up with your email to follow new studies for HER2 GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple threat: immunotherapy and targeted drug join chemo to fight HER2+ gut cancers
Disease control Recruiting nowThis phase 2 study is testing whether adding two newer drugs—pembrolizumab (an immunotherapy) and trastuzumab (a targeted therapy)—to standard chemotherapy can help people with HER2-positive esophageal or stomach cancer that can be surgically removed. About 49 adults will receive…
Matched conditions: HER2 GENE MUTATION
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New combo therapy aims to stop rare HER2-positive salivary gland cancer in its tracks
Disease control Recruiting nowThis study tests whether adding the targeted drug T-DM1 to standard chemoradiation can prevent HER2-positive salivary gland cancer from returning after surgery. About 37 adults with advanced but removable tumors will receive the drug alongside standard care. Researchers will trac…
Matched conditions: HER2 GENE MUTATION
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in first human test
Disease control Recruiting nowThis early-phase trial tests a new drug called 177Lu-RAD202, which is a radioactive antibody designed to seek out and deliver radiation directly to HER2-positive cancer cells. The study involves 30 adults with advanced solid tumors that have not responded to standard treatments. …
Matched conditions: HER2 GENE MUTATION
Phase: EARLY_PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo therapy targets Hard-to-Treat GI cancers
Disease control Recruiting nowThis early-phase trial tests a combination of two drugs, neratinib and fam-trastuzumab deruxtecan (Enhertu), in people with advanced stomach, esophageal, or other gastrointestinal cancers that have a specific marker called HER2. The study aims to find the safest dose and see if t…
Matched conditions: HER2 GENE MUTATION
Phase: PHASE1 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC